• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Scale FinanceScale Finance Logo, Interim CFO, Part Time CFO Services, Accounting Support, Temporary CFO, Accounting Bookkeeping Services

Interim CFO, Part Time CFO Services, Accounting Support, Temporary CFO, Accounting Bookkeeping Services

Charlotte · Raleigh – Durham · Chapel Hill · Triad · Southern Pines · Coastal Carolina
Closing the GAAP to Scale Your Business
The FINACA Logo
919-230-4667
Scale Finance, LLC, Financing, North Myrtle Beach, SC
  • Home
  • Services
    • CFO & Controller Services
    • Capital Raise Services
    • Business Valuations
    • Mergers & Acquisitions
    • Professional Consultations at No Cost
  • Professionals
    • Partners
    • Charlotte Team
    • Raleigh – Durham – Chapel Hill Team
    • Greensboro-Southern Pines
    • Coastal Carolina Team
  • Client Experience
    • Closed Capital Raise Transactions
    • Closed M&A Transactions
    • Client Endorsements
    • Information Technology
    • Healthcare, Biopharma & Medical Device
    • Services, Energy, Industrial
    • Consumer, Retail, Media
    • Real Estate
    • Private Equity Groups
  • Recent News
  • Knowledge Bank
    • Best Practices in Scaling Companies
    • Entrepreneurial Management Skill- Building
    • Financial Management
    • Mergers & Acquisitions
    • Regulatory Developments
    • Venture Capital
  • Contact Us
    • Charlotte
    • Raleigh – Durham – Chapel Hill
    • Triad – Southern Pines
    • Coastal Carolina
  • Joining Our Firm

Patterns in Capital Structure for Biotech Companies – Pre-Revenue Through IPO

Source; Mark Mirkin, Rimon Law

The public securities markets and the underwriters that lead biotech companies into them dictate a common capital structure suitable for IPOs, which structure almost always deviates starkly from the capital structure of the venture at inception and during its growth phase. Startups frequently commence corporate life structured as limited liability companies with a few founders as members owning equity interests, which members are then often joined by investors in a “friends and family” round of seed financing who receive economic interests bereft of equity stakes. When the company shows promise, it often raises its first round of external financing in a convertible debt offering, with investors receiving promissory notes convertible into equity interests upon the occurrence of future financing. When the company shows further promise after having wisely deployed the capital provided first by the founders, then by friends and family and then by angel investors, it would be fortunate to attract the attention of a venture capital company. Because most venture capital companies invest for preferred stock positions, the company almost always converts its corporate structure from that of a limited liability company to that of a corporation in order to close a venture financing. The members and holders of economic interests become holders of common stock – sometimes voting common stock for the members and non-voting common stock for the holders of economic interests – while preferred stock is issued to the venture capital company investors. If all goes well, a biotech venture will need to raise investment capital in successive rounds of funding; often an early stage venture capital company investor will invest again in a subsequent round, with each round attracting other venture capital companies to the party. For those companies that manage to attract an underwriter willing to underwrite an IPO, the capital structure imposed on the young company will comprise the following, often after a restructuring and recapitalization exercise:

Prior to the IPO, the biotech’s outstanding capital stock will include common stock predominantly owned by founders and angels, and convertible preferred stock owned by institutional investors. Many disparate parties often hold options and warrants to purchase common stock. Conversion of the pref-erred stock occurs automatically upon closing of the IPO, such that the only capital stock outstanding of the freshly-public company will be common stock.

The common stock will be voted to determine the directors on the company’s board of directors. It will be entitled to receive dividends which may be declared by the directors. In the event of liquidation, the common stock is entitled to receive proportionately all assets available for distribution to shareholders after the payment of all debts and other liabilities.

The post-IPO corporate charter often contains a provision enabling the directors to issue preferred stock without shareholder approval, similar to the provision in the charter when the company converted from being a limited liability company to being a corporation. The directors have discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, applicable to each series of preferred stock. This charter provision allowing for the issuance of preferred stock eliminates delays and expenses associated with shareholder voting and provides flexibility for possible acquisitions, future financings and other corporate purposes. Preferred stock authorization could make it more difficult for a third party to acquire – or could discourage a third party from seeking to acquire – a majority of the venture’s common stock.

Many biotech companies upon going public will enter into a registration rights agreement with the historical holders of their common stock – from founders to venture capital companies that receive common stock upon conversion of their preferred stock – that enable such holders to compel the company to register their shares with the S.E.C. so that they can participate in public market selling along with members of the public that purchase the IPO shares of registered common stock.

Delaware is by far the most popular jurisdiction for the charter of a company going public. Among the many reasons for that is that Delaware’s corporate statutes prevent a publicly-held Delaware corporation from engaging in a business combination such as a merger with any interested shareholder – a holder of a 15% or greater equity stake — for three years following the date the person became an interested shareholder unless that person attained that status with approval of the company’s board of directors, the business combination is approved by the board of directors and shareholders, or the interested shareholder acquired at least 85% of the company’s outstanding shares when he/she/it became an interested shareholder.

Understanding a biotech’s pre- and post-IPO capital structure provides a useful backdrop to a discussion of corporate governance provisions, which will be the subject of the next article in the series.

About Scale Finance

Scale Finance LLC (www.scalefinance.com) provides contract CFO services, Controller solutions, and support in raising capital, or executing M&A transactions, to entrepreneurial companies. The firm specializes in cost-effective financial reporting, budgeting & forecasting, implementing controls, complex modeling, business valuations, and other financial management, and provides strategic help for companies raising growth capital or considering M&A/recapitalization opportunities. Most of the firm’s clients are growing technology, healthcare, business services, consumer, and industrial companies at various stages of development from start-up to tens of millions in annual revenue. Scale Finance LLC has offices throughout the southeast including Charlotte, Raleigh/Durham, Greensboro, Wilmington, Washington D.C. and South Florida with a team of more than 40 professionals serving more than 100 companies throughout the region.

 

Primary Sidebar

Knowledge Bank

5 Rules for an A+ Board Meeting for Investor-backed Companies

Understanding & Using Your Cash Flow Statement

Why Business Valuations are Helpful (& What do they Typically Cost)?

Managing Merchant Fees – Role of Zero Fee Processing

Can Accountants Value a Business?

Personal Guarantees – Should You Grant One?

10 Pieces of Advice When Someone Wants to Buy Your Company

Convertible Note Financing – Payback Time

Due Diligence Fiasco – A Look Back at HP-Autonomy

Applying for Business Loans – Hard Credit Checks

7 Ways a Business Name Generator Can Help Entrepreneurs

Citizenship by Investment Overview

Understanding the True Cost of Employee Turnover

How to Think About Valuation When Raising Venture Capital

What it Takes to Shift to a Recurring Revenue Model in Hardware & Software

Differences Between Major SBA Loan Programs – SBA 7(a) vs. SBA 504

5 Reasons Entrepreneurs Don’t Get Funded (Which Are Not Their Fault)

Balancing Profitability Versus Growth

Bootstrapping Your SaaS Business – What’s Changing

Best Options for Small Company Loans

Explore the Knowledge Bank…

Secondary Sidebar

Recent News

SF Closes Acquisition of Midwest Outdoor Resorts for Travel Resorts of America

Scale Finance Advises FX HedgePool on $8M Series A Funding

Scale Finance Closes $7 Million Senior Debt Financing for Travel Resorts of America

Scale Finance Advises on Acquisition of Falcone Crawl Space & Structural Repair

Congrats to Payzer for Closing $23 Million Equity Financing

SF Client Headbands of Hope Closes Strategic Growth Investment

SF Assists Semper Investment Company in Acquisition of ACM Removal

SF Client SentryOne Acquired by SolarWinds (NYSE: SWI)

Scale Finance Assists GPM with Acquisition by Netsmart

SF Client Broadstep Behavioral Health Continues National Growth Through Acquisitions

SF Client Impact Financial Systems (IFS) Acquired by iPipeline

Scale Finance Assists TrueLearn with Investment by LLR Partners

Scale Finance Assists Textum Weaving with Investment by Quad-C

Scale Finance Closes Debt Financing for Horizon Eye Care

Scale Finance Closes Acquisition of Horsepower Site Services by MCG Civil

Scale Finance Closes Growth Financing for Celerity

Scale Finance Advises on Acquisition of Reliant Transport

More News…

Footer

Media

Scale Finance Managing Director Dave Gilroy interviewed on WSIC Radio (local Fox affiliate)

/wp-content/uploads/2014/02/David-Gilroy-Interview-Local-Biz-Now-2-7-14.mp3

Entrepreneurial Tips

  • Funding Tips from Scale Finance
  • CIE Life Sciences Panel Discussion
  • Why Use Fractional CFO Services

Sign Up—Finance Bulletin

Monthly insights into corporate finance for entrepreneurial companies

Sending

FINACA is a nationwide network of independent finance and accounting consulting firms focused on delivering exceptional client service.

FINACA is a nationwide network of independent finance and accounting consulting firms focused on delivering exceptional client service.

Return to top of page

Copyright © 2008–2023 Scale Finance, LLC
Securities and offering services through Charles Towne Securities, LLC. Members FINRA and SIPC.